Journal of Clinical Virology
Volume 38, Issue 1 , Pages 14-18 , January 2007

Human Papillomavirus testing for the management of low-grade cervical abnormalities in the UK—Influence of age and testing strategy

  • K.S. Cuschieri

      Affiliations

    • Specialist Virology Centre, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh EH16 4SA, United Kingdom
    • Corresponding Author InformationCorresponding author. Tel.: +44 131242 6039; fax: +44 242 6008.
    • ,
  • C. Graham

      Affiliations

    • The Epidemiology and Statistics Core, Wellcome Trust Clinical Research Facility, The University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU, United Kingdom
    • ,
  • C. Moore

      Affiliations

    • Specialist Virology Centre, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh EH16 4SA, United Kingdom
    • ,
  • H.A. Cubie

      Affiliations

    • Specialist Virology Centre, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh EH16 4SA, United Kingdom

Received 31 March 2006 ,Revised 13 October 2006 ,Accepted 18 October 2006.

References 

  1. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infection. J Clin Virol. 2005;32S:S16–S24
  2. Cuschieri KS, Cubie HA, Whitley MW, Seagar AL, Arends MJ, Moore C, et al. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Pathol. 2004;57:68–72
  3. Eltoum IA, Chieng DC, Roberson J, Partridge EE. Reflex human papillomavirus infection testing detects the same proportion of cervical intraepithelial neoplasia grade 2-3 in young versus elderly women. Cancer. 2005;105:194–198
  4. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, the Netherlands, France and Italy. J Natl Cancer Inst. 2005;97:888–895
  5. Kinney WK, Maon MM, Hurley LB, Ransley JE. Where's the high-grade neoplasia? The importance of minimally abnormal Papanicolaou diagnoses. Obstet Gynecol. 1998;91:973–976
  6. Kulasingam SL, Kim JJ, Lawrence WF, Mandelblatt JS, Myers ER, Schiffman M, et al. Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study. J Natl Cancer Inst. 2006;18:92–100
  7. Legood RL, Gray A, Wolstenholme J, Moss S. Lifetime effects, costs and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: modelling study. BMJ. 2006;14:79–85
  8. Liquid Based Cytology/Human Papillomavirus Cervical Pilot Studies Group. Effect of testing for human papillomavirus as triage during screening for cervical cancer: observational before and after study. BMJ. 2006;332:83–85
  9. Monsonego J, Bohbot JM, Pollini G, Krawec C, Vincent C, Merignargues I, et al. Performance of the Roche AMPLICOR® Human Papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear. Gynecol Oncol. 2005;99:160–168
  10. Rana DN, Marshall J, Desai M, Kitchener HC, Perera DM, El Terafi H, et al. Five-year follow-up of women with borderline and mildly dyskaryotic cervical smears. Cytopathology. 2004;15:263–270
  11. Sargent A, Bailey A, Wheeler P, Kitchener H, Corbitt G. A comparison of the Digene Hybrid Capture 2 assay and the Roche AMPLICOR® Human papillomavirus (HPV) test for the detection of high-risk HPV genotypes in DNA extracts from liquid-based cytology samples collected from women whose cytology was graded borderline.. In: 21st international papillomavirus conference. Mexico City, February 21–26. 2004;[abstract]
  12. Schiffman M, Castle PE. When to test women for human papillomavirus. BMJ. 2006;14(332):61–62

PII: S1386-6532(06)00399-4

doi: 10.1016/j.jcv.2006.10.007

Journal of Clinical Virology
Volume 38, Issue 1 , Pages 14-18 , January 2007

Article Tools

* Image Usage & Resolution